adalimumab-adbm 40 MG per 0.8 ML Prefilled Syringe

RxCUI
2640883
RxNorm name
adalimumab-adbm 40 MG per 0.8 ML Prefilled Syringe
Display name
adalimumab-adbm 40 MG per 0.8 ML Prefilled Syringe
Full name
adalimumab-adbm 40 MG per 0.8 ML Prefilled Syringe
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:38:47

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761058Cyltezoadalimumab-adbm351(k) InterchangeableRx2026-06-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.

Matched openFDA labels page 1 of 1 · 3 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
CyltezoADALIMUMAB-ADBMBoehringer Ingelheim Pharmaceuticals, Inc.115ea79b-7209-7f19-b35d-36ec0828fbf52026-05-22Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2640883
Adalimumab-adbmADALIMUMAB-ADBMBoehringer Ingelheim Pharmaceuticals, Inc.62f39a7c-00df-4519-a8d4-39bbd0a649ed2025-11-12Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2640883
Adalimumab-adbmADALIMUMAB-ADBMQUALLENT PHARMACEUTICALS HEALTH LLCf9986706-9c75-4335-a54f-09d7716dbcef2024-11-12Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2640883

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set IDRxNorm stringTTYSPL versionLabelEffective
115ea79b-7209-7f19-b35d-36ec0828fbf5adalimumab-adbm 40 MG per 0.8 ML Prefilled SyringeSY17These highlights do not include all the information needed to use CYLTEZO safely and effectively. See full prescribing information for CYLTEZO. CYLTEZO ® (adalimumab-adbm) injection, for subcutaneous use Initial U.S. Approval: 2017 CYLTEZO (adalimumab-adbm) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betw20260303
115ea79b-7209-7f19-b35d-36ec0828fbf50.8 ML adalimumab-adbm 50 MG/ML Prefilled SyringeSCD17These highlights do not include all the information needed to use CYLTEZO safely and effectively. See full prescribing information for CYLTEZO. CYLTEZO ® (adalimumab-adbm) injection, for subcutaneous use Initial U.S. Approval: 2017 CYLTEZO (adalimumab-adbm) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betw20260303
115ea79b-7209-7f19-b35d-36ec0828fbf5adalimumab-adbm 40 MG in 0.8 ML Prefilled SyringePSN17These highlights do not include all the information needed to use CYLTEZO safely and effectively. See full prescribing information for CYLTEZO. CYLTEZO ® (adalimumab-adbm) injection, for subcutaneous use Initial U.S. Approval: 2017 CYLTEZO (adalimumab-adbm) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betw20260303
62f39a7c-00df-4519-a8d4-39bbd0a649ed0.8 ML adalimumab-adbm 50 MG/ML Prefilled SyringeSCD5These highlights do not include all the information needed to use ADALIMUMAB-ADBM safely and effectively. See full prescribing information for ADALIMUMAB-ADBM. ADALIMUMAB-ADBM injection, for subcutaneous use Initial U.S. Approval: 2017 This product is CYLTEZO ® (adalimumab-adbm). CYLTEZO (adalimumab-adbm) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that th20251112
62f39a7c-00df-4519-a8d4-39bbd0a649edadalimumab-adbm 40 MG in 0.8 ML Prefilled SyringePSN5These highlights do not include all the information needed to use ADALIMUMAB-ADBM safely and effectively. See full prescribing information for ADALIMUMAB-ADBM. ADALIMUMAB-ADBM injection, for subcutaneous use Initial U.S. Approval: 2017 This product is CYLTEZO ® (adalimumab-adbm). CYLTEZO (adalimumab-adbm) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that th20251112
62f39a7c-00df-4519-a8d4-39bbd0a649edadalimumab-adbm 40 MG per 0.8 ML Prefilled SyringeSY5These highlights do not include all the information needed to use ADALIMUMAB-ADBM safely and effectively. See full prescribing information for ADALIMUMAB-ADBM. ADALIMUMAB-ADBM injection, for subcutaneous use Initial U.S. Approval: 2017 This product is CYLTEZO ® (adalimumab-adbm). CYLTEZO (adalimumab-adbm) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that th20251112
f9986706-9c75-4335-a54f-09d7716dbcefadalimumab-adbm 40 MG per 0.8 ML Prefilled SyringeSY3These highlights do not include all the information needed to use ADALIMUMAB-ADBM safely and effectively. See full prescribing information for ADALIMUMAB-ADBM. ADALIMUMAB-ADBM injection, for subcutaneous use Initial U.S. Approval: 2017 This product is CYLTEZO ® (adalimumab-adbm). CYLTEZO (adalimumab-adbm) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that th20241112
f9986706-9c75-4335-a54f-09d7716dbcef0.8 ML adalimumab-adbm 50 MG/ML Prefilled SyringeSCD3These highlights do not include all the information needed to use ADALIMUMAB-ADBM safely and effectively. See full prescribing information for ADALIMUMAB-ADBM. ADALIMUMAB-ADBM injection, for subcutaneous use Initial U.S. Approval: 2017 This product is CYLTEZO ® (adalimumab-adbm). CYLTEZO (adalimumab-adbm) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that th20241112
f9986706-9c75-4335-a54f-09d7716dbcefadalimumab-adbm 40 MG in 0.8 ML Prefilled SyringePSN3These highlights do not include all the information needed to use ADALIMUMAB-ADBM safely and effectively. See full prescribing information for ADALIMUMAB-ADBM. ADALIMUMAB-ADBM injection, for subcutaneous use Initial U.S. Approval: 2017 This product is CYLTEZO ® (adalimumab-adbm). CYLTEZO (adalimumab-adbm) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that th20241112